Background Elevated D-dimer concentrations are associated with an increased risk of venous thromboembolism (VTE). However, they may also provide prognostic value. The present analysis sought to study the association of D-dimer levels with VTE event rates and the efficacy of betrixaban versus enoxaparin in the APEX trial. Methods Hospitalized acutely medically ill subjects ( n ?=?7,513) were randomized in a double-dummy double-blind fashion to either extended-duration oral betrixaban (80?mg once daily for 35-42 days) or standard dose subcutaneous enoxaparin (40?mg once daily for 10?±?4 days) for venous thromboprophylaxis. D-dimer was assessed using a central core laboratory measurement. Results For every 0.25 µg/mL increase in D-dimer concentration, there was a 2% increase in the relative risk of experiencing the primary efficacy endpoint (asymptomatic deep vein thrombosis [DVT], symptomatic DVT, nonfatal pulmonary embolism, or VTE-related death) in both the betrixaban ( p ?
View details for DOI 10.1055/s-0037-1615288
View details for PubMedID 31249924
View details for PubMedCentralID PMC6524856